Compare Stocks: LPTX, NLTX, LYEL, and IRD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRD Opus Genetics	$3.72 -1.1%	$3.79	$1.04 ▼ $5.81	$307.46M	0.59	933,726 shs	513,283 shs
LPTX Leap Therapeutics		$2.05	$0.00 ▼ $0.00	$84.95M	-0.06	40.67 million shs	760.56 million shs
LYEL Lyell Immunopharma	$13.74 -3.0%	$13.42	$10.19 ▼ $45.00	$336.63M	-0.04	129,592 shs	88,997 shs
NLTX Neoleukin Therapeutics	$36.98 +3.3%	$33.72	$2.03 ▼ $14.36	$347.54M	1.11	50,104 shs	342,639 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRD Opus Genetics	-3.09%	-0.53%	-1.31%	-24.35%	+238.74%
LPTX Leap Therapeutics	0.00%	0.00%	0.00%	0.00%	+204,999,900.00%
LYEL Lyell Immunopharma	-4.77%	+5.35%	-1.12%	-25.50%	+34.06%
NLTX Neoleukin Therapeutics	-2.05%	+4.04%	-9.66%	+9.75%	+75.92%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRD Opus Genetics	$3.72 -1.1%	$3.79	$1.04 ▼ $5.81	$307.46M	0.59	933,726 shs	513,283 shs
LPTX Leap Therapeutics		$2.05	$0.00 ▼ $0.00	$84.95M	-0.06	40.67 million shs	760.56 million shs
LYEL Lyell Immunopharma	$13.74 -3.0%	$13.42	$10.19 ▼ $45.00	$336.63M	-0.04	129,592 shs	88,997 shs
NLTX Neoleukin Therapeutics	$36.98 +3.3%	$33.72	$2.03 ▼ $14.36	$347.54M	1.11	50,104 shs	342,639 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRD Opus Genetics	-3.09%	-0.53%	-1.31%	-24.35%	+238.74%
LPTX Leap Therapeutics	0.00%	0.00%	0.00%	0.00%	+204,999,900.00%
LYEL Lyell Immunopharma	-4.77%	+5.35%	-1.12%	-25.50%	+34.06%
NLTX Neoleukin Therapeutics	-2.05%	+4.04%	-9.66%	+9.75%	+75.92%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IRD Opus Genetics	2.89	Moderate Buy	$10.69	187.43% Upside
LPTX Leap Therapeutics	1.00	Sell	N/A	N/A
LYEL Lyell Immunopharma	2.78	Moderate Buy	$42.00	205.68% Upside
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LPTX, NLTX, LYEL, and IRD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	IRD Opus Genetics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/7/2026	IRD Opus Genetics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$10.00 ➝ $9.00
8/6/2026	LYEL Lyell Immunopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$36.00
7/29/2026	IRD Opus Genetics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
7/22/2026	LYEL Lyell Immunopharma	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$44.00
7/17/2026	IRD Opus Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	LYEL Lyell Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	IRD Opus Genetics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/6/2026	IRD Opus Genetics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
7/6/2026	IRD Opus Genetics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
6/23/2026	IRD Opus Genetics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$10.00

(Data available from 8/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IRD Opus Genetics	$14.20M	21.65	N/A	N/A	($0.16) per share	-23.25
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	$0.91 per share	N/A
LYEL Lyell Immunopharma	$40K	8,415.75	N/A	N/A	$11.68 per share	1.18
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IRD Opus Genetics	-$49.59M	-$1.35	N/A	N/A	N/A	-1,091.82%	-338.88%	-150.13%	N/A
LPTX Leap Therapeutics	-$67.56M	-$1.22	N/A	N/A	N/A	N/A	-247.44%	-146.51%	N/A
LYEL Lyell Immunopharma	-$274.45M	-$12.83	N/A	N/A	N/A	-920,285.25%	-87.60%	-67.85%	N/A
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	N/A	N/A	N/A	-37.22%	-30.91%	N/A

Latest LPTX, NLTX, LYEL, and IRD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2026	Q2 2026	IRD Opus Genetics	-$0.1567	-$0.14	+$0.0167	-$0.14	$2.63 million	$0.76 million
8/6/2026	Q2 2026	LYEL Lyell Immunopharma	-$1.94	-$1.9180	+$0.0220	-$1.92	$0.00 million	$0.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IRD Opus Genetics	N/A	12.19	12.19
LPTX Leap Therapeutics	N/A	1.34	1.34
LYEL Lyell Immunopharma	N/A	7.23	7.23
NLTX Neoleukin Therapeutics	N/A	15.33	15.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IRD Opus Genetics	14.97%
LPTX Leap Therapeutics	30.46%
LYEL Lyell Immunopharma	66.05%
NLTX Neoleukin Therapeutics	52.37%

Insider Ownership

Company	Insider Ownership
IRD Opus Genetics	11.70%
LPTX Leap Therapeutics	4.30%
LYEL Lyell Immunopharma	6.20%
NLTX Neoleukin Therapeutics	1.58%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IRD Opus Genetics	14	82.65 million	72.98 million	N/A
LPTX Leap Therapeutics	40	41.44 million	39.66 million	N/A
LYEL Lyell Immunopharma	270	24.50 million	22.99 million	Optionable
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data

LPTX, NLTX, LYEL, and IRD Headlines

Recent News About These Companies

(NGNE) Proactive Strategies

October 18, 2024 | news.stocktradersdaily.comN

Neurogene concludes merger deal with Neoleukin Therapeutics

December 20, 2023 | pharmaceutical-technology.comP

Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?

December 20, 2023 | finance.yahoo.com

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

December 14, 2023 | finance.yahoo.com

Neoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and Dates

December 4, 2023 | benzinga.com

Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…

October 5, 2023 | markets.businessinsider.com

Neoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

September 26, 2023 | finanznachrichten.de

Neoleukin Thera (NASDAQ: NLTX) should be up 500% - it’s actually up 7%

September 26, 2023 | dhakatribune.comD

Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

September 22, 2023 | finance.yahoo.com

Investing in Neoleukin Therapeutics Inc. [NLTX]: What You Must Know

August 21, 2023 | knoxdaily.comK

Neoleukin Therapeutics Recent Insider Activity

August 18, 2023 | benzinga.com

BAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics Inc

August 18, 2023 | finance.yahoo.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCU

August 8, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTX

August 1, 2023 | markets.businessinsider.com

Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc

July 28, 2023 | finance.yahoo.com

Moore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law Firm

July 26, 2023 | benzinga.com

Analysts review Neoleukin Therapeutics Inc.’s rating

July 26, 2023 | knoxdaily.comK

ALERT: The M&A Class Action Firm Continues Investigating the Merger – SCU, NLTX, HCCI, CCF

July 24, 2023 | kentuckytoday.comK

Baker Bros. Advisors Now Owns 19.99% of Neoleukin Therapeutics

July 24, 2023 | 247wallst.com

An Analysis of Neoleukin Therapeutics Inc. (NLTX)’s Potential Price Growth

July 19, 2023 | knoxdaily.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPTX, NLTX, LYEL, and IRD Company Descriptions

Opus Genetics NASDAQ:IRD

$3.72 -0.04 (-1.06%)

Closing price 04:00 PM Eastern

Extended Trading

$3.72 +0.00 (+0.13%)

As of 05:52 PM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Leap Therapeutics NASDAQ:LPTX

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Lyell Immunopharma NASDAQ:LYEL

$13.74 -0.43 (-3.03%)

Closing price 04:00 PM Eastern

Extended Trading

$13.76 +0.02 (+0.15%)

As of 04:10 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Neoleukin Therapeutics NASDAQ:NLTX

$36.98 +1.18 (+3.30%)

As of 08/12/2026

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LPTX, NLTX, LYEL, and IRD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LPTX, NLTX, LYEL, and IRD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LPTX, NLTX, LYEL, and IRD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPTX, NLTX, LYEL, and IRD Company Descriptions

Opus Genetics NASDAQ:IRD

Leap Therapeutics NASDAQ:LPTX

Lyell Immunopharma NASDAQ:LYEL

Neoleukin Therapeutics NASDAQ:NLTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LPTX, NLTX, LYEL, and IRD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LPTX, NLTX, LYEL, and IRD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LPTX, NLTX, LYEL, and IRD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPTX, NLTX, LYEL, and IRD Company Descriptions

Opus Genetics NASDAQ:IRD

Leap Therapeutics NASDAQ:LPTX

Lyell Immunopharma NASDAQ:LYEL

Neoleukin Therapeutics NASDAQ:NLTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools